EMC Instytut Medyczny S.A.
- Address
- Ul. Grunwaldzka 156, 60-309 Poznan, Poland
Digestive System Diseases
At EMC Instytut Medyczny S.A. in Poznan, clinical research in digestive system diseases is centered on ulcerative colitis. The trials are designed to evaluate whether new treatment options can improve symptom control and clinical response for people living with this chronic inflammatory condition.
- Research focused on ulcerative colitis and related gastrointestinal inflammation
- Studies assessing the effectiveness of new therapies for better disease control
- Clinical work aimed at improving treatment outcomes in digestive system disorders
This area of research helps determine how well emerging therapies may support patients with active ulcerative colitis and improve everyday disease management.
Respiratory Tract Diseases
Clinical trials at this site also address respiratory tract diseases, with a focus on asthma. The research is evaluating whether combination inhaled treatments can provide better symptom relief and overall control for adolescents and adults affected by this common airway condition.
- Studies in asthma and broader respiratory disease care
- Trials examining the effectiveness of inhaled treatment combinations
- Research aimed at improving breathing control and treatment benefit
These studies contribute to understanding how new approaches may help people with asthma achieve more reliable symptom management and improved quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EMC Instytut Medyczny S.A.
lock Showing 1 of 69 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 5 | Unknown | 2018-07-26 | 2026-05-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.